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Trimethoprim.sulfamethoxazole in cyst fluid from autosomal dominant
polycystic kidneys. Cyst infection in patients with autosomal-dominant
polycystic kidney disease (ADPKD) is often refractory to therapy, in
part because of the limited entry of commonly used antibiotics into cyst
fluid. To study the efficacy of tnmethoprim-sulfamethoxazole in cyst
infection, cyst fluid was obtained by percutaneous aspiration or at
surgery from eight patients with ADPKD receiving trimethoprim-
sulfamethoxazole. Cysts were categorized as nongradient or gradient
by cyst-fluid sodium concentration. Trimethoprim-sulfamethoxazole
concentrations within cysts were determined and cyst fluid inhibitory
and bactericidal titers were assessed in vitro against Escherichia coli,
Proteus mirabilis and Streptococcus fecalis. The mean cyst fluid
trimethoprim and sulfamethoxazole concentrations were 15.2 g/ml and
42.5 p.g/ml, respectively. Preferential accumulation of trimethoprim
was observed in gradient cysts, exceeding serum levels more than
eightfold. Sulfamethoxazole penetrated cysts to a lesser extent, with
concentrations ranging from 10 to 70 percent of the serum level. Cyst
fluid sampled prior to trimethoprim-sulfamethoxazole administration
(control) demonstrated no antibacterial activity, while cyst fluid inhib-
itory and bactericidal titers following antibiotic administration were
1:32 or greater in most instances. These studies indicate that trimetho-
prim-sulfamethoxazole is likely to be efficacious in the treatment of cyst
infection in polycystic kidneys.
Autosomal-dominant polycystic kidney disease (ADPKD) is
a common hereditary condition characterized by bilaterally
enlarged kidneys due to the presence of multiple fluid-filled
cysts of varying size. Urinary tract infection is a frequent
occurrence in patients with ADPKD [1—6]. While the precise
incidence of infectious involvement of the cysts themselves is
unknown, this complication is often refractory to standard
antimicrobial therapy, resulting in considerable morbidity [6—SI.
One possible reason for the difficulty in eradicating cyst infec-
tion is the failure of many antibiotics to achieve therapeutic
concentrations within cyst fluid [9]. Whether local factors
within the cyst environment (such as pH) modify the acitivty of
antibiotics is unknown.
A previous study from our institution has shown that "thera-
peutic" levels of trimethoprim-sulfamethoxazole can be achieved
in the cyst fluid of patients with ADPKD despite the presence of
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renal dysfunction [101. In the present study we measured
trimethoprim-sulfamethoxazole concentrations in cyst fluid from
patients (7 noninfected, 1 infected) receiving the drug and also
evaluated the antibacterial activity of such fluid in vitro against
common urinary tract pathogens, representative of those most
frequently involved in cyst infection. This is the first study to
report cyst fluid bactericidal titers as a means of evaluating
potential antibiotic efficacy of drugs used for the treatment of
cyst infection.
Methods
Patients
Six men and two women with a mean age (±sE) of 44±4 years
who had ADPKD were studied. All patients had typical features
of the disease including bilaterally enlarged cystic kidneys and
a positive family history. After giving informed consent, gb-
merular filtration rate was estimated by endogenous creatinine
clearance, inulin clearance, or technetium-99m diethylenetri-
amine pentaacetic acid (DTPA) clearance. One patient had
normal renal function, four had variable degrees of renal
insufficiency, and two were on chronic dialysis for end-stage
renal failure. In addition, one patient who had received a
successful kidney transplant required removal of her solitary
polycystic kidney nine weeks postoperatively because of per-
sistent renal infection. Her other polycystic kidney had been
removed one year prior to transplant for similar reasons.
Characteristics of the patient population are shown in Table 1.
Antibiotic administration
All patients were given trimethoprim-sulfamethoxazole. In
the seven noninfe&ed patients, 160 mg trimethoprim and 800
mg sulfamethoxazole was administered orally twice daily as a
combined preparation for periods of 3 to 40 days (mean SE =
12 4 days). The only infected patient (patient 1) received 180
mg trimethoprim and 900 mg sulfamethoxazole, as well as 1000
mg ampicillin, intravenously every 6 hours for 17 days as
treatment for a presumed cystic kidney infection characterized
by fever, flank pain, and positive blood and urine cultures
growing Escherichia coli.
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Table 1. Patient profile and types of cy sts sampled
Patient no. Age/sex
GFR
mt/mm Circumstances of aspiration
Number of cysts aspirated following
i Mt-MA treatment
.Duration of
treatment
daysNongradient Gradient Indeterminate
I 51/F 33
(allograft)
Unilateral nephrectomy for persistent
infection following successful renal
transplant
17 1 0 17
2 42/M Dialysis Pretransplant bilateral nephrectomy 13 19 7 3
3 44/M 70 Symptomatic; percutaneous aspiration 1 1 0 40
4 32/F 83 Symptomatic; cyst marsupialization 4 0 5 8
5 39/M 39 Symptomatic; percutaneous aspiration 2 1 1
6 54/M 20 Symptomatic; percutaneous aspiration 5 0 0
7 32/M Dialysis Symptomatic; percutaneous aspiration 3 1 1 7
8 61/M 34 Symptomatic; percutaneous aspiration 1 1 1 7
Subtotal 46 24 15
percent of total 54 28 18
Collection of samples
Cyst fluid was obtained by ultrasound-guided aspiration of 3
to 8 large cysts with a 22 gauge needle (5 patients) or at surgery
(3 patients). Fluid obtained at surgery was principally from
superficial (subcapsular) cysts, although deeper cysts were also
aspirated through the cavities of unroofed superficial cysts.
Patients underwent either procedure for indications unrelated
to this study (Table 1). Cyst fluid was obtained from two
patients at the time of nephrectomy for presumed cystic kidney
infection (patient 1) or pretransplant preparation due to a
history of recurrent, urinary tract infection (patient 2). Cysts
from the remaining patients were sampled at the time of cyst
decompression for the management of pain [111. There were no
complications of cyst aspiration or surgical removal of the
kidneys. Serum samples were obtained as close to the time of
aspiration or surgery as possible, usually within 15 to 30
minutes. An aliquot of cyst fluid was incubated on a blood agar
plate to screen for contamination by aerobic bacteria. In
addition, cyst fluid from patient 1 was cultured for anaerobic
bacteria, aerobic bacteria and fungi on appropriate media. The
remaining fluid was stored at —70°C in tightly capped glass vials
for later analysis.
Six months following surgery for cyst aspiration, patient 4
underwent repeat aspiration following 320 mg trimethoprim and
1600 mg sulfamethoxazole given intravenously 12 hours and 3
hours prior to cyst sampling. Analysis of six cysts derived from
this patient are considered separately.
Analysis of cyst fluid
Cyst fluid sodium concentrations were measured by flame
photometry (KLiNa Flame, Beckman Instruments, Inc.,
Fullerton, California, USA). Cyst fluid sodium concentrations
greater than 100 mEqlliter were designated as "non-gradient"
cysts and cysts with values less than 20 mEq/liter were catego-
rized as "gradient" cysts. Cysts with sodium concentrations
between 20 and 100 mEq/liter or with insufficient volume for
sodium determination were designated as "indeterminate."
Trimethoprim in cyst fluid and serum was assayed in duplicate
by an agar bioassay [12], with a lower limit of sensitivity of 1
p.g/ml. For the trimethoprim assay paraaminobenzoic acid and
thymidine phosphorylase were added to the medium to give a
final concentration of 100 g/ml and 0.1 lU/mi, respectively.
Paraaminobenzoic acid was added to inhibit the effect of
sulfamethoxazole while thymidine phosphorylase was added to
inactivate any residual thymidine present in the medium. Sam-
ples containing ampicillin from patient 1 were pre-treated with
penicillinase (Difco) to give a final concentration of 1600 U/ml.
Sulfamethoxazole concentrations were determined by the chemi-
cal method of Bratton and Marshal [13]. Only the free (thera-
peutically active) sulfonamide, and not the conjugated com-
pound, was measured, with detectable levels above 0.2 p.gIml.
The presence of other antimicrobials in the specimen did not
interfere with the chemical assay for sulfonamides. Cyst fluid
trimethoprim-sulfamethoxazole concentrations are reported as
the mean SE, and concentrations in gradient versus nongra-
dient cysts were compared utilizing the Mann-Whitney u-test
for nonparametric data. Significance was defined as P < 0.05.
In vitro assessment of cyst fluid activity
In six of the eight patients (patients 3 to 8) fluid was also
obtained by percutaneous aspiration from 1 to 3 cysts prior to
the administration of trimethoprim-sulfamethoxazole. Cyst fluid
inhibitory and bactericidal titers were determined by serial
macrobroth dilution, both before (control) and after trimetho-
prim-sulfamethoxazole treatment, against standard test orga-
nisms Escherichia coli, Proteus mirabilis and Streptococcus
fecalis, common pathogens in urinary tract infection. The
method used is similar to the serum inhibitory and bactericidal
titer [14], except that cyst fluid was tested instead of serum. The
inhibitory titer was taken as the maximal dilution of the cyst
fluid that inhibited growth of the organism. The bactericidal
titer represented the maximal dilution of the cyst fluid which
provided 99.9% killing of the organism. The minimum inhibi-
tory concentrations (MICs) of trimethoprim and sulfamethox-
azole alone against these organisms were as follows: Esche-
richia coli, 0.31 and 4.7 p.g/ml; Proteus mirabilis, 0.74 and 3.8
g/ml, respectively, and Streptococcus fecalis, 0.35 xg/ml
(trimethoprim only). The MICs of the combination of trimeth-
oprim/sulfamethoxazole were as follows: Escherichia coli,
0.051/0.94 Lg/ml; Proteus mirabilis, 0.028/0.56 p.g/ml; Strepto-
coccus fecalis, 0.10/1.84 ji.glml.
Trimethoprim Sulfamethoxazole
Total
cyst/serum
15.2 3.2 (40)
3.9 1.3
42.5 2.4 (85)
0.43 0.03
Nongradient
cyst/serum
11,9 2.7 (31)
2.6 0.6
52.6 3.6 (46)
0.46 0.03
Gradient
cyst/serum
42.8 17.Oa (4)
8.5 3.0
24.6 2.0 (24)
0.36 0.09
Indeterminate 13.8 9.6 (5) 39.9 2.8 (15)
Results
Among the eight patients, fluid was sampled from a total of 96
cysts, 11 cysts prior to trimethoprim-sulfamethoxazole admin-
istration and 85 cysts following treatment. All cysts were
sterile, including those from patient 1 who was receiving
trimethoprim-sulfamethoxazole for clinical cyst infection. Of
the 11 cysts aspirated prior to trimethoprim-sulfamethoxazole
therapy, 7 were nongradient, 3 were gradient and 1 was
indeterminate. Those cysts sampled during or after antibiotic
administration included 46 nongradient, 24 gradient and 15
indeterminate (Table 1). In 44 cysts the trimethoprim concen-
trations were not performed, including the 39 cysts from patient
2. In addition, the volume of fluid from some cysts was
insufficient to perform comprehensive analysis, accounting for
the fact that complete data are unavailable for all cysts.
Cyst fluid trimethoprim-sulfamethoxazole concentration
Antibiotic concentrations in nongradient, gradient and inde-
terminate cysts are shown in Table 2. The average trimethoprim
concentration in cyst fluid was 15.2 3.2 g/ml (N = 40). This
excludes a single gradient cyst with a concentration of 216
ig/m1 since this value was greater than two standard deviations
from the mean. When compared to simultaneous serum tnmeth-
oprim concentrations, the mean cyst/serum ratio for all subjects
was 3.9 1.3. Cyst/serum trimethoprim ratios for all cysts
showed a wide range, however, extending from 0.5 to 15.3. The
mean cyst/serum ratio of trimethoprim in nongradient cysts was
2.6 0.6, while that in gradient cysts was 8.5 3.0.
Compared with trimethoprim, cyst/serum sulfamethoxazole
ratios were consistently lower with an average value of 0.43
0.03 (P < 0.005). The range for individual cyst concentrations
was 10 percent to 70 percent of the serum sulfamethoxazole
concentration. In nongradient cysts there was a mean cyst!
serum ratio for sulfamethoxazole of 0.46 0.03. In gradient
cysts the average sulfamethoxazole cyst/serum ratio was 0.36
0.09. Figure 1 shows each patient's mean trimethoprim and
sulfamethoxazole concentrations in nongradient and gradient
cysts. Preferential accumulation of trimethoprim in gradient
cysts compared to nongradient cysts is evident, the difference
being significant (P < 0.005). In contrast, sulfamethoxazole
accumulation is significantly less in gradient cysts than in
nongradient ones (P < 0.001).
Fig. 1. Cyst fluid trimethoprim-sulfamethoxazole concentrations. A.
Mean trimethoprim concentrations. B. Mean suifamethoxazole concen-
trations. In both panels lines connect mean "nongradient" and "gradi-
ent" cyst antibiotic levels for each patient. Two patients had no
"gradient" cysts samples. ( ) denotes the patient number from Table 1.
Patient 2 did not have trimethoprim determinations. * represents a
single cyst with trimethoprim = 216 ig/ml.
Concentrations of trimethoprim and sulfamethoxazole were
well above the MIC for the test organisms E. coli, P. mirabilis
and S. fecalis in all cysts sampled. Cyst fluid levels of both
drugs could not be correlated with the measured glomerular
filtration rate. In fact, excellent concentrations were achieved
in all patients, including those on dialysis. Likewise, the anti-
biotic concentrations in cyst fluid were unrelated to the duration
of treatment over the 3 to 40 day range. Instead, adequate levels
were achieved within a short time. In this regard patient 4, who
underwent repeat cyst marsupialization 6 months following the
initial procedure, had trimethoprim-sulfamethoxazole levels
exceeding the MIC for E. coli, P. mirabilis and S. fecalis in all
6 cysts within 12 hours of instituting treatment. In this patient,
cyst/serum trimethoprim and sulfamethoxazole ratios were 0.49
.03 and 0.40
.03, respectively.
Cyst fluid inhibitory and bactericidal titers
Cyst fluid inhibitory and bactericidal titers both before and
during trimethoprim-sulfamethoxazole administration are sum-
marized in Figure 2. With the exception of the single cyst from
patient 7, fluid sampled from 11 cysts prior to trimethoprim-
sulfamethoxazole administration showed no in vitro antibacte-
rial activity against the common urinary tract pathogens E. coli,
P. mirabilis and S. fecalis as both the cyst fluid inhibitory and
bactericidal titers were consistently less than a 1:2 ratio for
these organisms. Patient 7 had recently received an unknown
antibiotic for an upper respiratory infection prior to cyst sam-
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Table 2. Mean cyst fluid trimethoprim-sulfamethoxazole
concentrations (g/ml)
Elzinga et al
A B
Cyst sulfamethoxazole
Numbers in parentheses indicate the number of cysts sampled
a Excludes single gradient cyst with trimethoprim concentration =
216 g/ml
100
75
50
25
15
10I
(I)C
3a
I
0
Nongradient Gradient Nongradient Gradient
Trimethoprim-sulfamethoxazole in renal cysts 887
AAAA A AAAA AAAAA AAAAA • AAAAA AAAA
AAAA A AAAA AAAAA AAAAA A4AA
MMbIt..,T&t• D.t.,kId.ITIt• h,hlbfte,yTIt I.t.fldd.tTItI b,ldbItO,ynt., I.t.,kId.tTftø
Escherichia coil Proteus mirabitis Streptococcus fecalis
FIg. 2. Cyst fluid inhibitory and bactericidal titers versus Excherichis
coli, Proteus mirabilis and Streptococcus fecalis. Each data point
represents fluid from a sing! cyst. Symbols are: (Lx) fluid sampled prior
to trimethoprim-sulfamethoxazole administration; (•) fluid sampled
following trimethoprim-sulfamethoxazole adminstration; (*) a single
cyst from patient 7 who had recently received another antibiotic prior to
sampling.
pling, which may explain the observed antibacterial activity of
that single cyst fluid sample.
Following tnmethoprim-sulfamethoxazole administration fluid
from all cysts evaluated demonstrated excellent inhibitory
activity against the three organisms, with a titer usually in
excess of 1:32. In a few instances the turbidity of the cyst fluid
precluded determination of the inhibitory titer. With one excep-
tion, adequate cyst fluid bactericidal titers also were achieved
against E. co/i and P. mirabilis, being greater than or equal to
1:32 in most instances. In one cyst the fluid bactericidal titer
against P. mirabilis was less than 1:2. Since the concentrations
of both trimethoprim and sulfamethoxazole in that cyst were
comparable to those in other cysts, the reason for the lack of
bactericidal activity is unclear and may represent a technical
artifact. While demonstrating inhibitory activity, cyst fluid
obtained following trimethoprim-sulfamethoxazole was not bacte-
ricidal against S. fecalis. Fluid from the six cysts sampled from
patient 4 following 12 hours of treatment already demonstrated
adequate inhibitory and bactericidal titers against E. co/i and P.
mirabilis, equaling or exceeding 1:16 in most cysts (data not
included in Fig. 2).
Discussion
It is conservatively estimated that between 50 and 70 percent
of all patients with ADPKD will experience at least one clinical
urinary tract infection during the course of their disease [1, 3,
41. When upper urinary tract infection with cyst involvement
occurs, eradication of the infection is often unsuccessful despite
prolonged antibiotic therapy. This may lead to the development
of perinephric abscess necessitating surgical drainage or ne-
phrectomy in a high percentage of cases. Over a 42 month
period, Sweet and Keane observed 8 of 24 patients with
ADPKD undergoing chronic hemodialysis who developed symp-
tomatic urinary tract infection [61. Despite prompt and pro-
longed treatment with appropriate antibiotics, five patients
subsequently developed perinephric abscess. Three of these
patients died. Similarly, antibiotic therapy failed in four of five
patients with infected polycystic kidneys reported by Waters,
Hershman and Klein [81. These reports underscore the thera-
peutic difficulties and adverse consequences of infection in
polycystic kidneys. Whether infection also enhances cyst for-
mation and accelerates the deterioration of renal function is
unclear [151.
While difficult to document in the literature, it is thought that
cyst infection is ususally caused by common urinary tract
pathogens, by the ascending route, following lower urinary
tract colonization. Thus, Escherichia co/i and other enteric
organisms can be anticipated. Data by Schwab confirms this
clinical impresssion [16].
Most antibiotics penetrate polycystic cysts poorly, which
may account for the refractory nature of cyst infections. Muther
and Bennett observed low or absent cyst fluid accumulation of
representative members of the aminoglycoside, penicillin, and
cephalosporin classes of antibiotics [9].
Several studies have indicated that the cysts in ADPKD are
focal dilations of nephron segments whose epithelial lining
maintains many of the functional and histologic properties of
the nephron segment of origin [17—20]. This has allowed for the
identification of two different populations of cysts [17, 19].
"Nongradient" cysts have fluid with sodium concentrations
and pH approximating that of plasma and are felt to arise from
proximal tubular segments. In contrast, "gradient" cysts are
able to maintain steep transepithelial electrolyte gradients re-
sulting in fluid with a low sodium concentration and a high
hydrogen ion concentration similar to the distal tubular envi-
ronment. This distinction has clinical relevance in terms of
antibiotic accumulation within the cysts. Schwab et a! docu-
mented cyst fluid concentrations of clindamycin, a nonpolar
and lipid-soluble agent, to be inversely related to cyst fluid pH
[21]. They proposed that high accumulations in the acidic
environment of gradient cysts was due to non-ionic diffusion
and ion trapping and predicted similar behavior with other
lipid-soluble antibiotics with high pKa values.
In the present study we have documented that trimethoprim-
sulfamethoxazole, a lipophilic agent with an alkaline pKa,
consistently achieves therapeutic concentrations within the
cyst fluid of polycystic kidneys. Excellent concentrations of
trimethoprim were attained in both gradient and nongradient
cysts, with enhancement over serum levels of almost fourfold.
Preferential accumulation of trimethoprim was observed in
gradient cysts where levels exceeded those in serum by more
than eightfold. In contrast, sulfamethoxazole entered both
nongradient and gradient cysts in concentrations less than those
achieved in serum, being 46 percent and 36 percent, respec-
tively, of the serum level. The efficacy of trimethoprim-sull-
amethoxazole for cyst infection was further demonstrated by in
vitro determination of the bacteriostatic and bactericidal pro-
perities of the cyst fluid derived from ADPKD patients receiv-
ing the drug. Fluid obtained from both nongradient and gradient
cysts prior to antibiotic administration showed no intrinsic
antibacterial activity. Fluid obtained following trimethoprim-
sulfamethoxazole administration consistently demonstrated ad-
equate inhibitory and bactericidal titers against the standard
test organisms. Such assays provide a more comprehensive
analysis which takes into account the interaction between the
antibiotic and local factors within the cyst environment. While
not previously employed in this setting, such assays have been
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used extensively in patients with infective endocarditis [22, 23].
In that setting, serum bactericidal titers of 1:8 or greater are
generally regarded as satisfactory and usually indicate an
adequate drug regimen. In one respect the current study does
not mimic the clinical setting in that cyst infection was not
present. Thus, we have not excluded a potential role for active
inflammation in altering antibiotic penetration and activity
within cysts as well as the antibiotic sensitivities peculiar to a
particular infecting organism. In addition, we have not deter-
mined the efficacy of trimethoprim and sulfamethoxazole alone
relative to their combined presence. Therefore, the observed
antibacterial properties of the cyst fluid may have been due, in
large part, to the activity of trimethoprim which was present in
high concentrations in all cysts. While the cyst fluid concentra-
tion of trimethoprim was consistently above the MIC for most
trimethoprim-sulfamethoxazole susceptible organisms [24], with
sulfamethoxazole this was less reliable. In this regard, failure to
achieve cyst sterilization has been reported in a patient infected
with a trimethoprim-resistant E coli [25]. Even when in vitro
sensitivities predict cure with trimethoprim-sulfamethoxazole,
occasional therapeutic failures may occur. In this situation,
other lipid soluble agents such as chloramphenicol or ciproflo-
xacin may be useful [26, 27].
In summary, trimethoprim-sulfamethoxazole with its favor-
able aerobic gram-negative spectrum is likely to be efficacious
in the treatment of most cyst infections due to common urinary
tract pathogens. This is based on drug concentrations achieved
in both proximal and distal cysts, as well as in vitro assessment
of cyst fluid antibacterial activity. This appears to be true even
in patients with far advanced renal-insufficiency. Cyst fluid
inhibitory and bactericidal titers represent a novel approach to
the evaluation of potentially useful drugs for cyst infection and
may prove useful in predicting the therapeutic response of
patients with infected cysts.
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